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Abstract 
Despite great medical advancement in the treatment of cancer, cancer remains a disease of global significance. Chemo-
therapeutics can be very expensive and drain medical resources at a national level and in some cases the cost of treatment is 
so great that it prohibits their use by local health authorities. Drug resistance is also a major limiting factor to the successful 
treatment of cancer with many patients initially responding well but then becoming refractory to treatment with the same drug 
and in some case may become multi-drug resistant. The immune system is known to be important in the prevention of tumors 
by eliminating pre-cancerous or cancerous cells. This concept of immune surveillance has largely been super-ceded by the 
concept of immunoediting whereby the immune system imposes a selective pressure on tumor cells which may either control 
tumor growth or inadvertently select for tumor cells which have evolved to escape the immune response and which may induce 
tumor development. Stimulation of the immune system by vaccination offers many benefits in the treatment of cancer. It is highly 
cost effective and vaccines can be manipulated to include multi-antigens which in some cases may overcome equilibrium (and 
selective pressure) while also preventing the establishment of reactivated cancer cells, since cancer antigen-specific memory 
would be induced following the initial vaccination/booster phase. To date studies using vaccination as a treatment for cancer 
have been a little disappointing, probably due to insufficient level of immunogenicity. In this review we will discuss methods 
of manipulation of the immune system to increase the anti-cancer activity of dendritic cells in vivo and how monocyte derived 
dendritic cells may be manipulated ex vivo to provide more robust, patient-specific treatments. 
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Review
The global impact of cancer
Although new chemotherapeutics and greater diagnostic 
modalities have been developed, cancer remains a disease 
of global significance. There are around 12.7 million cases of 
cancer globally per year and this is estimated to increase to 26 
million per year by 2030 [1]. In 2010, 324,579 cases of Cancer 
were diagnosed in the UK and 157,275 deaths due to cancer 
were recorded [2]. The enormous cost of the disease suffered 
by governments and healthcare providers undoubtedly 
negatively impacts on other areas of health spending and 
in many cases newly developed drugs are too expensive for 
health authorities to purchase. The cost has been estimated to 
increase from £30000 to £40000 per patient per year between 
2010 and 2021 [3]. Furthermore, there is significant emerging 
resistance in many cases to chemotherapy [2], and a wealth of 
research has now been published which has shown the various 
mechanisms, detection and amelioration of resistance [4-9] by 
tumours to chemothereutic drugs. In the developing world 
many cancers remain untreated, due simply to the financial 
burden of current treatments, even more significant when 
considering that current global estimations of 12.7 million 
new cases of cancer per year are predicted to increase to 26 
million per year by 2030 [1]. Less expensive and effective new 
treatments would, therefore, be of obvious benefit in both the 
developed and developing world.
The concept of ‘immuno-surveillance’ in cancer biology is not 
new, and suggests that the immune response largely keeps in 
check the development of tumours. The development of efficient 
cancer vaccines therefore would appear to be a rational and 
cost effective therapeutic approach to the treatment of cancer.
The role of dendritic cells in adaptive immunity and 
vaccination
Antigen presenting cells (APCs) bridge the gap between innate 
and adaptive immunity, since APCs are innate immune cells 
which present antigens to the adaptive immune system (T 
and B lymphocytes). All APCs express major histocompatibility 
complex II (MHCII) as well as MHCI on their cell membranes, 
either constitutively or when activated. Antigen presentation 
to lymphocytes also requires a second (co-stimulatory signal) 
provided by molecules such as CD40, CD80 and CD86 which 
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engage with their counterparts (CD40 ligand and CD28) on 
the surface of T lymphocytes. The extent to which these 
molecules are expressed on the surface of APCs is paramount 
to the induction of a robust lymphocyte response to antigen. 
Another factor which may influence the lymphocyte response 
is the number of lymphocytes, with cognate T cell receptors, 
which can engage antigen on the APC surface and the most 
effective APCs have large surface areas due to membrane 
folding or cellular extensions (pseudopodia). 
Amongst APCs, only dendritic cells (DCs) have the ability 
to present antigens to naïve T lymphocytes [10-11] and B 
lymphocytes [12] and the amount of antigen presented by 
DCs is orders of magnitude greater than can be presented 
by macrophages [13]. DCs are therefore essential in the 
development of adaptive immunity and as such are important 
targets for vaccine antigens and adjuvants. In humans, DCs 
exist as a number of different sub-populations. These include 
Langerhans cells (LCs) and interstitial DCs (iDCs) (found in 
peripheral tissues), conventional DC (cDCs) which are further 
subdivided into type 1 and type 2 subsets (mDC1/mDC2) 
and plasmacytoid DCs (pDCs). In addition to these subsets, 
monocytes can be differentiated into monocyte derived DCs 
(MDDCs). Previously, the DC activation model suggested that 
precursors of LCs and iDCs migrate from blood into tissues and 
remain in an immature form until activated by pathogens or 
cytokines. Once activated these cells mature as they migrate 
to the draining lymph node where they present antigens to 
cognate lymphocytes [14-15]. However, more recent studies 
have indicated that this model may be too simplistic and 
that activation of DCs is more tightly controlled than was 
previously believed. For example a recent study has suggested 
that migrated rat pseudo-afferent DCs do not mobilize CD40 
stores to the cell membrane during interaction with steady 
state T lymphocytes but do mobilize CD40 to the immune 
synapse during allogeneic interaction but only for a limited 
time period [16] and a study by Geissmann [17] has also shown 
that MHCII stores in human LCs, migrating from inflamed skin 
into draining lymph nodes, remain cytoplasmic and only low 
levels of CD86 are detected on the cell membrane. While LCs 
may actually migrate into embryonic tissue and renew their 
population in situ, rather than from blood precursors [18] as 
was previously thought. However human DC populations are 
controlled in steady state conditions or activated and renewed 
in vivo, it is clear that much more of the biology of these DC 
subsets has yet to be revealed. Furthermore, the relative 
number of circulating DCs is very low with cDCs representing 
about <0.6% of the total peripheral blood mononuclear cells 
[19-20] and pDCs representing <0.4% [21]. It would not be a 
viable proposition to obtain DCs for in vitro manipulation (e.g., 
culturing with tumor antigen) since the numbers obtained 
would be much too low. With this in mind strategies have 
been developed which attempt to expand DC populations 
in vivo or manipulate MDDCs in vitro for replantation into the 
syngeneic patient (Figure 1).
Expanding DC populations in vivo as a mechanism for 
increased tumor immunogenicity
Cytokines 
Expanding the tumor antigen expressing DC populations 
would appear to be a rational approach to increasing the 
immunogenicity of cancer vaccines. One cytokine known 
to increase DC populations in lymphoid organs is fms-like 
tyrosine-kinase 3 ligand (Flt-3 ligand) [22-24] and daily 
administration of Flt-ligand has been shown to induce 
tumor regression and decrease tumor growth in mice with 
fibrosarcoma [25]. Flt-3 ligand and CD40 ligand were also 
shown to synergise to further expand DC numbers in mice with 
B10.2 or B10.5 tumors and this treatment led to a reduction 
in tumor growth or, in some cases, complete cure [26]. Flt-3 
ligand delivered via particle mediated transfection was also 
reported to inhibit the growth of MCA205-induced Sarcomas in 
mice and in this study increased CD11C+ cDCs were shown in 
tumor tissues as well as increased CD80 and MHCII expression 
[27]. Intra-nodal administration of Flt-3 ligand with antigen-
encoding RNA has also been reported to expand both cDC 
and pDC populations in a murine melanoma model [28]. In 
this study Flt-3 ligand and RNA induced expansion of nodal 
Th1 cells and increased tumor-specific CD8+ lymphocytes via 
antigen presentation by pDCs. The study also showed that 
70% of mice were cured of tumors following Flt-3 ligand/
RNA inoculation compared with only 11% cured following 
inoculation with RNA alone. This suggests that Flt-3 ligand 
may act as a DC adjuvant and that its inclusion in vaccine 
formulations may significantly enhance the immunogenicity 
of cancer vaccines.
Conversely, a study by Taylor et al., [29] has reported that 
progression of murine myeloproliferative disease (MPD) 
(induced by inactivating knock-in mutation in the RING finger 
domain of the c-Cbl E3 ubiquitin) is prevented by treatment 
with the Flt-3 kinase inhibitor AC220 and continued for as 
long as AC220 was administered. A study by Greystoke et 
al., [30] has also indicated that elevated Flt-3 ligand can be 
used to predict patients who develop neutropenic sepsis 
following chemotherapy against lymphoma. It is difficult to say 
whether there was a true causal link in this case but increases 
in plasma Flt-3 ligand in irradiated non-human primates 
was shown to be inversely correlated with neutropenia and 
when peak concentrations subsided this was correlated 
with a return of total blood cells counts to normal [31]. The 
treatment of neutropenia usually requires administration of 
granulocyte-colony stimulating factor (G-CSF) and a more 
stable form of recombinant G-CSF (Pegfilgrastim) has been 
developed [32]. Interestingly, administration of Pegfilgrastim 
to patients with gynaecological malignancies was shown to 
significantly increase circulating numbers of both cDCs and 
pDCs and as well as preventing neutropenic sepsis, caused by 
chemotherapy or possible future Flt-3 therapy, Pegfilgrastim 
appears to also expand DC populations in vivo in its own right. 
Therefore, studies to date have certainly highlighted the 
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immune-therapeutic potential of Flt-3 ligand in cancer but 
the use of Flt-3 to increase DC populations in vivo may have 
some draw-backs which need to be studied more thoroughly.
Although Flt-3 ligand is probably the best studied of mole- 
cules which expand DC populations in vivo others cyto-
kines have also been shown to have therapeutic potential. 
Macrophage inflammatory protein 3 alpha (MIP-3α) is an 
inflammatory chemokine which binds to CC-chemokine 
receptor 6 [33]. CCR6 is involved in the peripheral recruitment 
of immature Langerhands cells but it is CCR7 expression by 
mature DCs which induces their migration into the T cell areas 
of lymph nodes. Vaccination of mice with another cytokine 
granulocyte macrophage colony stimulating factor (GM-CSF) 
has been shown to have a very potent anti-tumor effect [34] 
and more recently Choi and Kim, [35] reported that plasmids 
encoding MIP-3 α and GM-CSF synergistically induced DC 
recruitment and increased T helper (Th) cell and cytotoxic 
T lymphocyte (CTL) activity at the site of murine EML/Muc1 
tumors and draining lymph. However, there is also evidence to 
suggest that tumours may suppress the host immune response 
via CCR7 expression and that expression of CCR7 may also 
be involved in metastasis [36], via ligation of the cytokine 
CCL21 [37]. It is clear therefore that the exact relationship 
between CCR7 expression, DCs and tumor regression, or 
indeed progression, needs further clarification.
Hohman et al., [38] were the first to identify a population of 
murine cells with both Natural killer cell (NK) cell and DC-like 
properties. These cells were termed NKDCs and later Chan et 
al., [39] reported that these cells produce IFNγ and kill cells 
expressing tumor antigen. Recently it has been shown that 
murine splenic NKDCc will proliferate in vitro when cultured 
with IL-21 and when replaced back into B16F10 (melanoma) 
tumor bearing C57BL/6 mice, the IL-21-cultured NKDCs were 
associated with a reduction in tumor size [40]. This may 
suggest that administration of IL-21 with tumor antigen 
could increase immunogenicity of cancer vaccines in vivo. 
However, one study has suggested that NKDCs may actually 
be a population of activated NK cells [41] and to date a similar 
NKDC population has not been reported in humans. IL-24 is 
another cytokine which has come into prominence recently 
Figure 1. The possible role of tumor antigen presentation by MDDC vaccination
The possible role of MDDC in tumor immunology with respect to the main cytokines and cell types is 
shown. (1) MDDCs presenting tumor antigen in conjunction with MHCI induce cognate CD8+ cytotoxic T 
lymphocytes (CTLs) to proliferate and kill tumor cells. (2) MDDCs presenting tumor antigen in conjunction 
with MHCII induce cognate CD4+ lymphocytes to differentiate into IFN-γ producing T helper 1 (Th1) subsets. 
(3) In addition the production of inflammatory cytokines such as IL-1β and IL-23 may induce differentiation 
of IL-17 producing Th17 subsets. (4) The synergistic effect of IFN-γ and IL-17 causes the production of 
chemokines such as interferon gamma inducing protein 10 (IP-10) (CXCL10) and monokine induced by 
interferon gamma (MIG) (CXCL9) by tumor cells. These cytokines stimulate migration of effector cells such as 
CD8+ CTLs and natural killer (NK) cells to the tumor.
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and is being investigated for its effect on many different 
cancers. IL-24 was first shown to be a protein product encoded 
by the melanoma differentiation-associated gene 7 (mda-7) 
[42] and was shown to have an anti-cancer effect in a number 
of human cancerous cell lines, including colorectal, prostate 
and cervical cancers [43]. Low expression of mda/IL-24 has 
been associated with increased nodal involvement in human 
breast cancer [44] and reduced survival of colorectal cancer 
patients [45]. One mechanism by which mda/IL-24 has anti-
cancer effects is by the promotion of cell death, such as the 
generation of ceramide, the production of reactive oxygen 
species and increased ER stress and mda-7 gene transfer via 
vectors such as adenovirus is currently being investigated 
[46]. High expression of mda-7 has also been shown in DCs 
within germinal centres of melanoma patients [47] which 
may suggest a different mechanism by which DCs suppress 
tumors via direct suppression rather than presentation of 
tumor antigens. However, increased expression of molecules 
essential for antigen presentation (HLA-DR, CD40 and CD80) 
was also measured in human DCs transfected with IL-24 
gene containing adenovirus and pulsed with lysates from 
SMMC-7721 (human hepatocellular carcinoma cells) [48]. 
This was also associated with increased production of IL-24, 
IL-12 and TNF-α and when these DCs were cultured with 
cytokines induced killer cells (ICK), they stimulated greater 
lytic activity by ICKs on SMMC-7721 cells. Once again these 
latter experiments suggest that IL-24 could be an important 
adjuvant if used in DC vaccines. 
Other molecules
Carthamus tinctorius (CT), or safflower, is used in Chinese 
traditional medicine to improve blood circulation. A study by 
Chang et al., [49] has reported that when murine bone marrow 
derived DCs were cultured with CT extract and pulsed with 
a JC cell (murine mammary adenocarcinoma) lysate, prior to 
administration into tumor bearing mice, they reduced tumor 
mass by >15%. This was also associated with a skewed Th 
response towards IFN-γ-producing Th1 cells and in vivo the 
CT-DC combination induced proliferation of CD8+ lymphocytes. 
An earlier study also reported that when CT polysaccharide 
was administered into mice bearing either S180 Sarcoma 
or LA795 lung tumors it was associated with a respective 
tumor inhibition or shrinkage and increased activity of CD8+ 
lymphocytes and natural killer (NK) cells, although DC activity 
was not studied [50]. Polyinosinic-cytidylic acid (poly (I:C)) 
has also been reported to increase DC populations removed 
from cervical cancer patients and when pulsed with E7 human 
papilloma virus antigen they increased surface expression of 
CD11C and CD86 [51]. It should be noted that although CD11C 
is a classic marker for myeloid DCs it is also has very important 
immunological properties. For example CD11C is a receptor 
for compliment protein iC3b and increases phagocytosis 
of iC3b-opsonized particles [52], while antibody blockade 
of CD11C on the surface of LCs ameliorates proliferation of 
allogeneic T lymphocytes [53], thus indicating a key role in 
the induction of innate and adaptive immunity. In another 
study, Poly: IC has also been shown to inhibit metastasis in a 
B16-F10 murine lung cancer model and was associated with 
increased DC maturation, increased CD8+ (CTL) activity and 
skewing of the immune response towards Th1/Th17 [54], while 
administration of a combination of the synthetic lipopeptide 
Pam3Cys with Poly: IC induced greater maturation of DCs and 
conferred tumor protection in mice [55]. 
The therapeutic potential for Monocyte derived DCs 
(MDDCs) in patient-specific cancer therapy
DCs can be derived ex vivo from blood monocytes (MDDCs) 
and since monocytes represent a large population of blood 
cells, numerous MDDCs can be derived in culture media 
containing granulocyte-monocyte colony stimulating factor 
(GM-CSF) and interleukin 4 (IL-4) [56]. Compared with their 
autologous monocytes, these MDDCs have increased surface 
area due to the development of dendrites (Figures 2A and 2B) 
and express a characteristic surface phenotype in which they 
express high levels of CD11C, CD83 and CD1a (which are not 
expressed by monocytes) and increased HLA-DR but very 
low levels of CD14, which is highly expressed by monocytes 
(Figures 2C-2G). These immature MDDCs can then be matured 
using various other cytokines including, TNF-α and IL-1β [57] 
while we have recently shown that human MDDCs mature in 
response to IFN-γ, IL-1β and novel cytokines, such as IL36β 
or IL36γ, allowing easy measurement of immunological 
parameters such as further increases in HLA-DR and CD83 
with a concurrent decrease in CD1a [58] (Figures 3E-3G). 
Furthermore, in humans and murine models, MDDCs appear 
to be a physiological population generated in vivo during 
inflammation [59,60], possibly serving to replenish spent 
peripheral DC populations. Autologous MDDCS can be safely 
injected back into recipients without inducing a host versus 
DC reaction (as long as utmost sterility can be achieved). 
This approach could allow patient specific vaccines to be 
developed according to tumor type and antigen expression. 
As such, a number of studies have now been reported to 
show that autologous monocyte derived DCs (MDDCs) pre-
loaded with relevant tumour antigen may be of some benefit 
in certain cancers [61-63]. 
Meta-analysis of the first 1000 MDDC vaccinees, with 
different tumours, demonstrated that about half exhibited a 
clinical response, and that MDDC vaccination was associated 
with virtually no adverse effects [64]. In another study, survival 
of patients with advanced melanoma was increased from 
5 months to 24 months following injection of autologous 
MDDCs loaded with melanoma antigen, and was significantly 
correlated with increased numbers of IFN-γ producing Th1 
lymphocytes [65]. It has also been reported [66] that MDDCs 
pulsed with carcinoembryonic antigen (CEA) induced 
antigen-specific T cell response in 8 out of 11 patients with 
colorectal cancer, and that this technique was far superior 
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Figure 2. IL-4 and GM CSF differentiates human monocytes into monocyte derived dendritic cells (MDDC) in vitro
After 5 days culture in IL-4 (10 ng/ml) and GM CSF (50 ng/ml) for 5 days, human monocytes (A) differentiate into 
immature MDDCs (B) which are larger and have characteristic dendrites (arrows). MDDCs are also phenotypically 
distinct from monocytes by expressing high levels of CD11C, CD1a, CD83 and HLA-DR (C-F) but not CD14 (G) on 
their cell membrane.
to MDDC transfection using CEA mRNA. Phase I clinical trials 
using the CEA loaded MDDCs in colorectal cancer patients 
indicated that they induced both a CD4+ and CD8+ effector 
response, but that T suppressor activity may have impacted 
on the full effect of the vaccine [67]. MDDCs loaded with 
CEA and melanoma associated antigen 3 (MAGE-3) induced 
significant increases in the killing of target cells by CTLs [68]. 
In a murine model of Melanoma therapy, MAGE-3 pulsed 
MDDC induced tumour specific CTL responses and inhibited 
tumour growth [69]. Recent studies have also shown that 
when mature MDDCs (designed to initiate Th1 cells) were 
pulsed with HER-2 antigen, they induced a robust IFN-γ 
response in addition to enhanced tumour cell-killing capacity 
in breast cancer patients. Furthermore, a recall response was 
measured after 52 months [70]. The data therefore, indicates 
that tumour antigen loaded MDDCs are a realistic strategy 
for future cancer therapy. Although DCs have been shown 
to be important in anti-melanoma immune responses [71] 
advanced melanoma is normally associated with immune 
suppression. However, one study has shown that human 
melanoma-conditioned media had no effect on the maturation 
of MDDCs, cytokine production (including Th1-inducing IL-12) 
or T cell proliferation [72]. This may suggest then that MDDC 
vaccines may be an ideally suited therapy for melanoma. 
Conversely, expression of Galectin-1 by lung cancr cell lines 
(A549 andNCI-H460) induces IL-10 producing MDDCs and 
IL-10-producing CD11C+ cells (DCs) have been shown to 
populate human lung tumors [73]. Since production of IL-10 
by DCs is associated with the differentiation of tolerogenic 
T cells, the study discussed above may suggest that MDDCs 
vaccines may have detrimental effects on therapy, although 
the immune status of MDDCs loaded with lung tumor antigen 
has not been reported.
By using tumour cell lysates [74], it has been demonstrated 
that a maximum of 5 mg/ml lysate can be loaded into 1 X 106 
MDDCs, and that a minimum of 1 mg/ml over a 24h culture 
period is required to produce measurable changes in DC 
immunogenicity. Such studies are critical to the future success 
of this strategy since the ability to deliver 1 effective vaccine 
dose may be necessary, as booster vaccines using tumour 
Rauch et al. Journal of Cancer Therapeutics & Research 2013, 
http://www.hoajonline.com/journals/pdf/2049-7962-2-20.pdf
6
doi: 10.7243/2049-7962-2-20
Figure 3. Immature MDDCs can be matured (to increase immunogenicity) by culture with specific cytokines
Compared to isotype controls (A) or unstimulated MDDCs cultured over the same time period (B). MDDCs cultured with IFN-γ, 
IL-1β, IL-36β or IL-36γ for 48h exibit further  increased expression of HLA-DR and CD83 but decreased expression of CD1a on 
their cell membranes (C-G). 
loaded MDDCs will be killed by memory CTLs. Although 
Dhodapkar et al., [75] have reported that a single injection 
of MDDCs is enough to induce a rapid, antigen specific and 
broad T cell response in humans and it is possible that that 
techniques which can boost the immunogenicity of a single 
injection vaccine will undoubtedly produce a greater clinical 
effect, and could contribute to overcoming the effect of 
suppressor activity.
 
Enhancing MDDC vaccination by adequately engineering 
the cell membrane
The membrane is composed of two leaflets which are 
themselves composed chiefly of lipids and other amphipathic 
molecules. For a long time these were considered to be neutral, 
with regard to the complex biochemical processes taking 
place within cells, but this view has now changed and it is 
well acknowledged that the lipid phase forming the boundary 
of cells is at least as important as the biochemistry taking 
place within cells. How the cell membrane is used by cells has 
become a much studied field of research and from these studies 
one can say that the lipid phase of the membrane has two 
main properties as it: (i) permits the stability required to allow 
transmembrane proteins to function properly and, (ii) allows 
exchanges with the extracellular medium via the mechanism 
of membrane recycling i.e., endocytosis and exocytosis. Both 
points (i) and (ii) have been shown to rely deeply on the bio-
physical properties of the cell membrane as well as the ability 
of cells to biologically control these processes. 
What matters in the case of antigen presentation is the 
potential ability to control membrane exocytosis. Membrane 
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recycling is driven by the ability of cells to form intracellular 
vesicles. The motor force behind the creation of vesicles resides, 
initially, in the membrane. The membrane is composed of two 
leaflets but these leaflets are not randomly composed, some 
lipids are preferentially located within the inner leaflet (e.g., 
phosphatidylsérine or phosphatidylethanolamine) whereas 
others remain in the outer leaflets (sphygomyelin). The non 
random composition of the membrane is attributed to ATP-
dependant lipid flippases ordering the membrane [76]. The 
creation of such an asymmetry in the type of lipids between 
the two leaflets induces a change in the physical properties of 
the membrane with an inner leaflet being more compacted 
than the outer one [77] (Figure 4). This compaction cannot 
be stored in the membrane, requiring the cell to release this 
energy and one way to do this is via the creation of intracellular 
vesicles. Naturally, one could argue that the model suggests 
that too much endocytosis should deplete the plasmalemma 
of the cell. However this never happens as exocytosis and 
endocytosis are two faces of the same coin and as a result 
will balance each other [78]. In essence the lipid asymmetry 
between the two membrane leaflets permits a low cost in ATP 
usage and a constant and smooth recycling of the membrane. 
How can this process be altered is down to how the physical 
properties of the membrane are affected. Let us assume that 
the lipid asymmetry is annihilated, endocytosis will stop. Now, 
if we reverse the lipid asymmetry – i.e., compact more the outer 
leaflet via the addition of exogenous lipid species compared to 
the inner leaflet; endocytosis will stop and exocytosis should 
be promoted [79-81]. In cells, not all receptors are displayed 
on the membrane, some stay within cells in endosomes 
or vesicles some may even recycle constantly between 
the membrane and the intracellular vesicles. By physically 
triggering membrane exocytosis it should be possible to empty 
all the intracellular compartments of their content leading to 
higher “expression” of antigens and relevant immunological 
molecules such as MHC and CD40. Experimentally, exocytosis 
can be promoted by simple incubation of phospholipids with 
cells such as phosphatidylcholine (PC) that is not translocated 
Figure 4. How membrane lipids influence endocytosis and exocytosis
The lipid number asymmetry induced fluid phase endocytosis : Sketch representing the current model that has been applied 
to living cells, links fluid phase endocytosis (A) and the membrane phospholipid number asymmetry maintained by a lipid 
flippase (the aminophospholipid translocase). In the left figure, the translocation of dark-head lipids into the inner leaflet 
induces a differential lipid packing between leaflets (namely a difference in surface pressures) leading to membrane bending 
and vesiculation. Note that it is assumed that the membrane recycling that occurs in cells, i.e., the exocytosis of vesicles of a 
size similar to endocytic vesicles (B), also allows the maintenance of the lipid asymmetry at the level of the plasmalemma. 
The relationship between the lipid number asymmetry and the vesicle radius can be determined fully considering the physical 
biology of the cell membrane see ref (75). A fundamental consequence resulting from the theory is that if the lipid asymmetry 
is inverted (i.e., if the outer leaflet contains more lipid than the inner leaflet) exocytosis should be promoted to balance the 
membrane stress. This was demonstrated by Rauch and Loughna (2005) using phosphatidylcholine (PC) as a phospholipid 
that is not translocated by the aminophospholipid translocase (i.e., flippase), the ability of PC to promote exocytosis was 
demonsrated in C2C12 myoblasts expressing the glucose transporter GLUT-1 (B). Upon incubation with cells, PC switched the 
balance of GLUT-1 from intracellular stores (in red) compartment to the membrane (in green). Note that phosphatidylserine 
(PS) that accumulates into the inner leaflet thanks to the aminophospholipid translocase activity does not generate exocytosis 
(C: control; PC: phosphatidylcholine; PS: phosphatidylserine).    
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demonstrated in myocytes by Rauch and Loughna (2005) 
(Figure 3).
Conclusion
Manipulation of MDDCs may lead to a more robust presentation 
of cancer antigens which may increase the impact of current 
(and very promising) syngeneic MDDC cancer vaccines.
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